Primal Health Databank: Study
| Entry No: | 0741 |
| Title: | Hepatitis B vaccine and the risk of CNS inflammatory demyelination in childhood |
| Author(s): | Mikaeloff Y, Caridade G, Suissa S, Tardieu M |
| Reference: | Neurology. 2009 Mar 10;72(10):873-80 |
| Place of Study: | France |
| Abstract: | This is a population-based case-control study where the cases were children with a first episode of acute CNS inflammatory demyelination in France (1994-2003). Each case was matched on age, sex, and geographic location to up to 12 controls, randomly selected from the general population. Information on vaccinations was confirmed by a copy of the vaccination certificate. The odds ratios (ORs) of CNS inflammatory demyelination associated with HB vaccination were estimated using conditional logistic regression. The rates of HB vaccination in the 3 years before the index date were 24.4% for the 349 cases and 27.3% for their 2,941 matched controls. HB vaccination within this period was not associated with an increase in the rate of CNS inflammatory demyelination (adjusted OR, 0.74; 0.54-1.02), neither >3 years nor as a function of the number of injections or brand type. When the analysis was restricted to subjects compliant with vaccination, HB vaccine exposure >3 years before index date was associated with an increased trend (1.50; 0.93-2.43), essentially from the Engerix B vaccine (1.74; 1.03-2.95). The OR was particularly elevated for this brand in patients with confirmed multiple sclerosis (2.77; 1.23-6.24). CONCLUSIONS: Hepatitis B vaccination does not generally increase the risk of CNS inflammatory demyelination in childhood. However, the Engerix B vaccine appears to increase this risk, particularly for confirmed multiple sclerosis, in the longer term. Our results require confirmation in future studies. |
| Keyword(s): | hepatitis B, multiple sclerosis, vaccination |
| Discussion: | No discussion mentioned for this entry |
| See Also: | No related entries mentioned for this entry |
Go Back | New Keyword Search